Compare AbCellera Biologics Inc (ABCL) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? AbCellera Biologics Inc trades at $7.2 (market cap $2.35B), while GraniteShares 2x Long NVDA Daily ETF trades at $30.09. The key difference: AbCellera Biologics Inc is trading nearer its 52-week high, GraniteShares 2x Long NVDA Daily ETF nearer its low. Which is the better fit depends on your goals.
| ABCL | NVDL | |
|---|---|---|
Market Cap | $2.35B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $8.12 | $43.02 |
52-Week Low | $2.78 | $21.76 |
Enterprise Value | $1.99B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $28.53 with a 1.1% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators remain neutral. The ETF has demonstrated significant volatility, with a 12% single-day drop in early June 2026 highlighting the risks of daily leverage reset. Recent stock splits (1:3 on June 25-26, 2026) have adjusted share structure.
The outlook for NVDL remains tied to NVIDIA's performance and AI sector momentum. While the ETF offers leveraged exposure to NVDA's gains, it carries substantial risk from daily rebalancing during market downturns. Investors should weigh the potential for amplified returns against the documented volatility and structural risks of leveraged ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
